Findings showed a 13.6% reduction in body weight in the semaglutide 25mg group compared with a 2.2% reduction in the placebo group.

Many compounding pharmacies are no longer allowed to make cheaper versions of semaglutide and other GLP-1 drugs. A doctor ...

The risk for ocular problems linked to different formulations of semaglutide appear to vary, according to a new study, which ...

Novo Nordisk stock popped Tuesday on reports it's asked the FDA to approve its weight-loss pill, an oral version of Wegovy.

We are pleased that the FDA has accepted our submission and look forward to working with regulatory authorities on what would be the first oral GLP-1 treatment for obesity." ...

With the company struggling to increase its production of the glucagon-like peptide-1 (GLP-1) treatments, finding additional capacity to manufacture oral semaglutide ... a GLP-1 pill from ...